Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1999 Jun 22;96(13):7300-5.
doi: 10.1073/pnas.96.13.7300.

Ezrin, a plasma membrane-microfilament linker, signals cell survival through the phosphatidylinositol 3-kinase/Akt pathway

Affiliations

Ezrin, a plasma membrane-microfilament linker, signals cell survival through the phosphatidylinositol 3-kinase/Akt pathway

A Gautreau et al. Proc Natl Acad Sci U S A. .

Abstract

ERM (Ezrin-Radixin-Moesin) proteins function as plasma membrane-actin cytoskeleton linkers and participate in the formation of specialized domains of the plasma membrane. We have investigated ezrin function in tubulogenesis of a kidney-derived epithelial cell line, LLC-PK1. Here we show that cells overproducing a mutant form of ezrin in which Tyr-353 was changed to a phenylalanine (Y353F) undergo apoptosis when assayed for tubulogenesis. While investigating the mechanism responsible for this apoptosis, we found that ezrin interacts with p85, the regulatory subunit of phosphatidylinositol 3-kinase (PI 3-kinase). Two distinct sites of ezrin are involved in this interaction, the amino-terminal domain containing the first 309 aa and the phosphorylated Tyr-353 residue, which binds to the carboxyl-terminal SH2 domain of p85. Cells producing Y353F ezrin are defective in activation of the protein kinase Akt, a downstream target of PI 3-kinase that protects cells against apoptosis. Furthermore, the apoptotic phenotype of these cells is rescued by production of a constitutively activated form of PI 3-kinase. Taken together, these results establish a novel function for ezrin in determining survival of epithelial cells by activating the PI 3-kinase/Akt pathway.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Apoptosis of LLC-PK1 cells producing Y353F ezrin in a tubulogenesis assay. (A) Immunodetection of endogenous and overproduced tagged ezrin in stable LLC-PK1 clones. P, E, and F cells were transfected, respectively, with the empty vector, the same vector encoding VSV-G tagged wild-type ezrin, or VSV-G tagged Y353F ezrin. Total cellular lysates were analyzed with either P5D4 mAb (Tag) or an anti-ezrin serum. (B) Cells were cultured for 7 days in presence of HGF in a collagen type I gel. Cultures were examined with Nomarski optics (Left) and for Hoechst 33258 staining (Right). In a collagen type I gel, only apoptotic bodies, as highlighted by pyknotic nuclei, were observed in F cell cultures, whereas P and E cells were able to form tubules in presence of HGF. (Bar = 20 μm.)
Figure 2
Figure 2
PI 3-kinase, which is required for survival, interacts with ezrin. (A) LY294002 induces apoptosis of LLC-PK1 cells in the tubulogenesis assay. Mean ± SD of an experiment performed in triplicate is plotted. LY294002 concentration is given in μM. (B) Coimmunoprecipitation of either wild-type or Y353F ezrin with the p85 subunit of PI 3-kinase. Lysates from P, E, or F clones were immunoprecipitated with p85 affinity-purified antibodies or rabbit IgG. The immunoprecipitates were analyzed with P5D4 mAb (Tag) or polyclonal anti p85 antibodies. (C) p85 binding to the amino-terminal domain of ezrin. A lysate from placenta was incubated with immobilized GST, GST–ezrin1–309 (GST-N), or GST–ezrin310–585 (GST-C). After washing, bound material was analyzed with polyclonal anti-p85 antibodies.
Figure 3
Figure 3
Activation of the PI 3-kinase/Akt pathway requires ezrin phosphorylation at residue Tyr-353. (A) Binding of p85 to a phosphorylated peptide corresponding to amino acids 348–358 of ezrin. A lysate from LLC-PK1 cells was incubated with either the beads alone (0), the immobilized peptide with the nonphosphorylated residue Tyr-353 (Y), or phosphorylated residue Tyr-353 (pY). Bound material was analyzed by Western blotting with polyclonal anti-p85 antibodies. (B) Binding of the carboxyl-terminal SH2 domain of p85 to the peptide containing the phosphorylated Tyr-353. The p85 amino-terminal SH2 (N) and the carboxyl-terminal SH2 (C) domains fused to GST were incubated with either the beads alone (O), the peptide with the nonphosphorylated residue Tyr-353 (Y), or the peptide with the phosphorylated residue Tyr-353 (pY). Bound material was analyzed by Western blotting with an anti-GST serum. (C) Analysis of Akt activity in three-dimensional cultures. Serum-starved LLC-PK1 clones were embedded in collagen gels. Lysates from P, E, and F cells treated with either LY294002 (+) or DMSO (−) were analyzed with either anti-phosphospecific Akt (Ser-473) (pAkt) or anti-Akt (Akt) polyclonal antibodies. Signals were analyzed by densitometry. The pAkt/Akt ratio was calculated and set to 100% for untreated P cells. Mean ± SEM of three independent experiments are presented in the histogram.
Figure 4
Figure 4
Rescue of the F cell survival defect by constitutively active PI 3-kinase and Bcl-2. One F clone was stably transfected with either the control hygromycin-resistance plasmid (Hygro), a cDNA encoding a CD2-p110 chimera (p110), or a cDNA encoding human Bcl-2. (A) Immunodetection of the chimeric CD2-p110 protein with anti-CD2 mAb Ox34. (B) Immunodetection of exogenous Bcl-2 with a human-specific anti-Bcl-2 mAb. (C) Survival and tubulogenesis were assessed as described in Fig. 1. (Bar = 15 μm.)

References

    1. Bretscher A, Reczek D, Berryman M. J Cell Sci. 1997;110:3011–3018. - PubMed
    1. Takeuchi K, Sato N, Kasahara H, Funayama N, Nagafuchi A, Yonemura S, Tsukita S. J Cell Biol. 1994;125:1371–1384. - PMC - PubMed
    1. Crepaldi T, Gautreau A, Comoglio P M, Louvard D, Arpin M. J Cell Biol. 1997;138:423–434. - PMC - PubMed
    1. Chen J, Cohn J A, Mandel L J. Proc Natl Acad Sci USA. 1995;92:7495–7499. - PMC - PubMed
    1. Kondo T, Takeuchi K, Doi Y, Yonemura S, Nagata S, Tsukita S, Tsukita S. J Cell Biol. 1997;139:749–758. - PMC - PubMed

Publication types